ArticleBMC anesthesiology2016
Effect of the ifenprodil administered into rostral anterior cingulate cortex on pain-related aversion in rats with bone cancer pain.
Article in BMC anesthesiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Polyamine Metabolism in Brain Health and Disease.Neuropharmacology and therapy · 2026Article
- Ifenprodil Reduced Expression of Activated Microglia, BDNF and DREAM Proteins in the Spinal Cord Following Formalin Injection During the Early Stage of Painful Diabetic Neuropathy in Rats.Journal of molecular neuroscience : MN · 2021Article
- Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.Anesthesia and analgesia · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the effect of rostral anterior cingulate cortex (rACC) administration with ifenprodil (NR2B receptor blocker) on bone cancer pain (BCP)-related aversion sentiment using the conditioned place avoidance experiments in rats.
methodsA total of 30 male Wistar rats without place preference were randomly assigned to three groups: control group (Group C, n = 10), BCP group (Group P, n = 10) and ifenprodil group (Group Ifen, n = 10). Three microliter MADB-106 cells were inoculated into right tibia bone marrow cavity in group P and Ifen, while the same dose of normal saline in group C as a control. Ifenprodil was administered into the rACC at the 14th day after inoculation in group Ifen and normal saline in group C and P. Mechanical stimulation pain thresholds of the rats' right hind paws were measured using Von Frey stimulation method at 1 day before injection of the tumor cells and at 3, 7,10, 12 and 14 days after the injection. The pain-related aversion in rats with BCP was determined by the conditioned place avoidance (CPA) test at 14 days after injection of ifenprodil.
resultsThe mechanical stimulation pain thresholds substantially decreased in rats in groups P and Ifen from 10 days to 14 days after the incubation with the MADB-106 cells (P < 0.05). There were significant differences in pain thresholds in groups P and Ifen compared to group C at 10, 12 and 14 days after inoculation (P < 0.05). The percentage of residence time in chamber A was (30 ± 4%) in group P, which was lower than (52 ± 5%) in group C (P < 0.05). After ifenprodil treatment, the percentage time in chamber A increased to (42 ± 5%), which was higher than that in group P and still lower than that in group C (P < 0.05).
conclusionIfenprodil administered into rACC as a selective NR2B antagonist can effectively alleviate pain-related aversion sentiment in rats with BCP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.